Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 2, 2021, covering events occurring on December 1, 2021. The company is incorporated in Delaware and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the departure of a senior executive:
- Resignation: Rudy Howard resigned as Chief Financial Officer and employee, effective December 1, 2021.
- Reason: Mr. Howard stated he had no disagreement with the Company regarding operations, policies, or practices.
Compensatory Arrangements and Unusual Items
In connection with the resignation, the Company entered into a Resignation Agreement with Mr. Howard containing the following terms:
- Severance: A cash payment at a rate of $325,000 per year, payable in monthly or bi-weekly installments through December 31, 2022.
- Bonus: Eligibility for a potential discretionary bonus for the year ending December 31, 2021, to be determined by the Compensation Committee.
- Benefits: Continued medical coverage at the same cost as active employees through December 31, 2022.
- Equity: Options scheduled to vest in December 2021 vested in full immediately. All vested options remain outstanding until their original expiration; unvested options are forfeited.
- Conditions: Payments are conditioned on Mr. Howard signing a release of claims and complying with post-employment restrictive covenants.
Investor Verification Checklist
- Verify the appointment of an interim or permanent replacement for the Chief Financial Officer role.
- Review the full text of the Howard Resignation Agreement (Exhibit 10.1) for specific restrictive covenants.
- Monitor future filings for the determination of the discretionary bonus amount.
- Assess the impact of the CFO departure on the company's financial reporting and operational stability.